Mink Therapeutics Stock Performance
| INKT Stock | USD 20.22 0.83 3.94% |
Mink Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -9.28, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Mink Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Mink Therapeutics is expected to outperform it. Use Mink Therapeutics semi variance, and the relationship between the treynor ratio and rate of daily change , to analyze future returns on Mink Therapeutics.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mink Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating forward-looking signals, Mink Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 6.31 | Five Day Return (9.31) | Year To Date Return 108.42 | Ten Year Return (82.46) | All Time Return (82.46) |
Last Split Factor 1:10 | Last Split Date 2025-01-28 |
1 | MiNK Therapeutics GAAP EPS of -0.70 misses by 0.09 | 05/15/2025 |
2 | Acquisition by Corvese Brian of 25000 shares of Mink Therapeutics subject to Rule 16b-3 | 05/23/2025 |
3 | Kalkine MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum | 06/10/2025 |
4 | MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - | 06/30/2025 |
5 | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell ... | 07/11/2025 |
6 | MiNK Therapeutics stock falls after William Blair downgrade | 07/14/2025 |
7 | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a ... | 07/15/2025 |
8 | Acquisition by Corvese Brian of 37500 shares of Mink Therapeutics at 2.27 subject to Rule 16b-3 | 07/17/2025 |
9 | Is MiNK Therapeutics Inc. a good long term investment - Free Investment Timing Strategies - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 3.4 M |
Mink Therapeutics Relative Risk vs. Return Landscape
If you would invest 750.00 in Mink Therapeutics on April 24, 2025 and sell it today you would earn a total of 1,355 from holding Mink Therapeutics or generate 180.67% return on investment over 90 days. Mink Therapeutics is currently generating 10.5419% in daily expected returns and assumes 93.9704% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Mink, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mink Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mink Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mink Therapeutics, and traders can use it to determine the average amount a Mink Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1122
| Best Portfolio | Best Equity | INKT | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 93.97 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Mink Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mink Therapeutics by adding it to a well-diversified portfolio.
Mink Therapeutics Fundamentals Growth
Mink Stock prices reflect investors' perceptions of the future prospects and financial health of Mink Therapeutics, and Mink Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mink Stock performance.
| Return On Equity | -12.39 | ||||
| Return On Asset | -1.12 | ||||
| Current Valuation | 85.78 M | ||||
| Shares Outstanding | 3.99 M | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (10.57 M) | ||||
| Net Income | (10.78 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (5.50) X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (2.46) X | ||||
| Market Capitalization | 83.9 M | ||||
| Total Asset | 5.72 M | ||||
| Retained Earnings | (144.18 B) | ||||
| Working Capital | (1.97 M) | ||||
About Mink Therapeutics Performance
Assessing Mink Therapeutics' fundamental ratios provides investors with valuable insights into Mink Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mink Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.89) | (1.98) | |
| Return On Capital Employed | 8.60 | 9.03 | |
| Return On Assets | (1.89) | (1.98) | |
| Return On Equity | 0.55 | 0.52 |
Things to note about Mink Therapeutics performance evaluation
Checking the ongoing alerts about Mink Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mink Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mink Therapeutics is way too risky over 90 days horizon | |
| Mink Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (10.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mink Therapeutics currently holds about 29.85 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88. | |
| Roughly 74.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Is MiNK Therapeutics Inc. a good long term investment - Free Investment Timing Strategies - jammulinksnews.com |
- Analyzing Mink Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mink Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mink Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mink Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mink Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mink Therapeutics' stock. These opinions can provide insight into Mink Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.